The information contained on this web page is only a summary of the information presented in more detail in the Notice of (I) Pendency of Class Action and Proposed Settlement; (II) Settlement Hearing; and (III) Motion for an Award of Attorneys’ Fees and Litigation Expenses (the “Notice”), which you can access by clicking here.  Since this web page is just a summary, you should review the Notice for additional details.

The Parties have reached a settlement of this action for $130,000,000 in cash (the “Settlement”) for the benefit of the Settlement Class (defined below). On November 17, 2021, the Court held a hearing on final approval of the Settlement and related matters and announced that it would approve the Settlement. On November 22, 2021, the Court entered a Judgment finally approving the Settlement and orders approving the proposed Plan of Allocation for the proceeds of the Settlement and awarding attorney's fees and litigation expenses to Plaintiffs’ Counsel.

Claims administration commenced in the fall of 2021 and was completed in the summer of 2023. On August 28, 2023, Lead Counsel filed its Distribution Motion. On December 27, 2023, the Court approved the Distribution Motion.

The Claims Administrator conducted an initial distribution of the settlement funds to eligible claimants in March 2024

If you have questions, you may call the Allergen Securities Litigation Help Line at  1-877-777-9328 or email info@AllerganDrugPricingSecuritiesLitigation.com.